Locations:
Min Investment:
Max Investment:
Target Investment:
2023
• Corporate VC of Eisai, a leading pharma that develops drugs for Alzheimer's disease & cancer • Investing with a strategic focus on aging-related diseases: neurodegeneration, cancer and others
2021 - 2022
• Investing in breakthrough science, platforms and proven teams to address unmet medical needs • Enabling win-win partnerships among portfolio companies, Eisai and collaborating pharma/VC firms
2024
2024
eGenesis is revolutionizing human organ xenotransplantation by providing CRISPR-edited, humanized pig organs.
2023
Iambic Therapeutics is pioneering the invention of physics-informed generative AI tools, aimed at drastically accelerating small molecule drug discovery.
2023
2023
Hyku Biosciences is pioneering the next generation of high precision covalent medicine by focusing non-cysteine amino acids (H,Y,K...) of "undruggable" targets.
2023
Tune Therapeutics is a global leader in developing CRISPR-based epigenome editing therapeutics for common diseases. https://www.genengnews.com/news/epigenetic-editing-in-non-human-primates-presented-by-tune-at-asgct/
2022
2022
RiboX Therapeutics is a circular RNA (circRNA) company, grounded in the pioneering work of its scientific founder Ling-Ling Chen in the biogenesis and functions of circRNA. With its unique protein-coding and non-coding functions, circRNA can overcome the current limitations of mRNA therapeutics. https://scholar.google.com/citations?user=0UNkhq4AAAAJ
2022
Casma Therapeutics is advancing the next generation bio-degradation innovation based on autophagy.
2022
2022
Delivering RNA drugs non-invasively across the blood-brain barrier (BBB) to treat neurodegenerative diseases. https://ophidion.com/
2020
Pyrotech is founded on the seminal work of Shao Feng, which illuminated the mechanism of 'Pyroptosis'. This novel form of cell death controls infection by activating strong immune responses. https://scholar.google.com/citations?user=wLg0PUQAAAAJ
2021
2021
Founded by proven entrepreneurs, Travera is using a breakthrough innovation from MIT to measure individual cancer cells’ weight and responses in order to match patients with drugs quickly in real clinics.